Physician profile
Jerome Sude
NPI 1982607727
$5,266.34
in general payments reported to CMS, 2019-2025
22 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,508 · 2020: $1,658 · 2021: $306 · 2022: $221 · 2023: $309 · 2024: $128 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $574.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,147.60 | 2019-2025 | Hydrus Microstent, Clareon |
| Coopervision INC. | $2,084.06 | 2019-2022 | |
| Oyster Point Pharma, INC. | $188.38 | 2022-2024 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $169.50 | 2019-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $137.86 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $105.81 | 2019 | |
| Novartis Pharmaceuticals Corporation | $66.30 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $61.85 | 2020-2022 | |
| Abbvie INC. | $53.01 | 2023-2025 | Durysta |
| Apellis Pharmaceuticals, INC. | $32.66 | 2023 | Syfovre |
| Mallinckrodt Hospital Products INC. | $31.26 | 2024 | Acthar |
| Rayner Intraocular Lenses Limited | $26.90 | 2025 | Rayone Aspheric, Rayone Emv, Rayner Cataract Set 1 |
| Bausch & Lomb Americas INC. | $19.23 | 2023 | Miebo, Vyzulta |
| Ani Pharmaceuticals, INC. | $18.79 | 2024 | Purified Cortrophin Gel |
| Recordati_rare_diseases_inc. | $18.28 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eusa Pharma (US) LLC | $18.28 | 2022 | |
| Shire North American Group INC | $16.05 | 2019 | |
| Kala Pharmaceuticals, INC. | $15.14 | 2021 | |
| Horizon Therapeutics Plc | $14.44 | 2020 | |
| Dompe US, INC. | $14.38 | 2022 | |
| Leadiant Biosciences, INC. | $13.70 | 2023 | Cystaran |
| Johnson & Johnson Surgical Vision, INC. | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome Sude listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.